Phillips Courtney

Insider · GC and Corp. Secretary · MAZE

Phillips Courtney files insider transactions with the SEC as a gc and corp. secretary of Maze Therapeutics (MAZE). We hold 2 disclosed purchases and sales filed since 17 July 2019, 2 of them in the last 90 days.

Files forMAZE
Disclosed buys and sells2 in all, 2 in the last 90 days
Last disclosure4 September 2026

Positions held

2 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 22 September 2025 — 3 September 2026GC and Corp. Secretary · Maze Therapeutics (MAZE)11 Form 4 lines · source: SEC Form 4
Filed 11 July 2019 — 1 September 2023General Counsel & Secretary · Atreca (BCEL)18 Form 4 lines · source: SEC Form 4

Everything they disclosed

29 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 1,738 shares of Maze TherapeuticsSEC Form 44 September 2026Common Stock · traded 2 September 2026 · filed 4 September 2026
▼ sold on the open market 243 shares of Maze TherapeuticsSEC Form 44 September 2026Common Stock · traded 2 September 2026 · filed 4 September 2026
▼ sold on the open market 1,990 shares of Maze TherapeuticsSEC Form 44 September 2026Common Stock · traded 3 September 2026 · filed 4 September 2026
▼ sold on the open market 22 shares of Maze TherapeuticsSEC Form 44 September 2026Common Stock · traded 3 September 2026 · filed 4 September 2026
exercised options over 11,000 shares of Maze TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
exercised options over 11,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 September 2026Restricted Stock Units · traded 1 September 2026 · filed 3 September 2026
was granted 32,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 3 March 2026
was granted 16,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 March 2026Restricted Stock Units · traded 2 March 2026 · filed 3 March 2026
was granted 32,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 2 March 2026 · filed 3 March 2026
was granted 16,000 shares of Maze Therapeutics (a derivative holding)SEC Form 43 March 2026Restricted Stock Units · traded 2 March 2026 · filed 3 March 2026
was granted 22,000 shares of Maze Therapeutics (a derivative holding)SEC Form 424 September 2025Restricted Stock Units · traded 22 September 2025 · filed 24 September 2025
▼ sold on the open market 7,061 shares of AtrecaSEC Form 43 April 2024Class A Common Stock · traded 1 September 2023 · filed 3 April 2024
▼ sold on the open market 4,076 shares of AtrecaSEC Form 44 August 2023Class A Common Stock · traded 2 August 2023 · filed 4 August 2023
was granted 130,000 shares of Atreca (a derivative holding)SEC Form 413 February 2023Employee stock option (right to buy) · traded 9 February 2023 · filed 13 February 2023
was granted 32,500 shares of AtrecaSEC Form 413 February 2023Class A Common Stock · traded 9 February 2023 · filed 13 February 2023
▼ sold on the open market 6,432 shares of AtrecaSEC Form 420 September 2022Class A Common Stock · traded 2 September 2022 · filed 20 September 2022
was granted 80,000 shares of Atreca (a derivative holding)SEC Form 415 June 2022Employee stock option (right to buy) · traded 13 June 2022 · filed 15 June 2022
returned to the issuer 80,000 shares of Atreca (a derivative holding)SEC Form 415 June 2022Employee stock option (right to buy) · traded 13 June 2022 · filed 15 June 2022
was granted 45,000 shares of Atreca (a derivative holding)SEC Form 415 June 2022Employee stock option (right to buy) · traded 13 June 2022 · filed 15 June 2022
returned to the issuer 45,000 shares of Atreca (a derivative holding)SEC Form 415 June 2022Employee stock option (right to buy) · traded 13 June 2022 · filed 15 June 2022
was granted 91,666 shares of Atreca (a derivative holding)SEC Form 415 June 2022Employee stock option (right to buy) · traded 13 June 2022 · filed 15 June 2022
returned to the issuer 91,666 shares of Atreca (a derivative holding)SEC Form 415 June 2022Employee stock option (right to buy) · traded 13 June 2022 · filed 15 June 2022
was granted 65,000 shares of Atreca (a derivative holding)SEC Form 415 June 2022Employee stock option (right to buy) · traded 13 June 2022 · filed 15 June 2022
returned to the issuer 65,000 shares of Atreca (a derivative holding)SEC Form 415 June 2022Employee stock option (right to buy) · traded 13 June 2022 · filed 15 June 2022
was granted 80,000 shares of Atreca (a derivative holding)SEC Form 428 December 2021Employee stock option (right to buy) · traded 23 December 2021 · filed 28 December 2021
was granted 35,500 shares of AtrecaSEC Form 413 September 2021Class A Common Stock · traded 9 September 2021 · filed 13 September 2021
was granted 80,000 shares of Atreca (a derivative holding)SEC Form 429 January 2021Employee stock option (right to buy) · traded 27 January 2021 · filed 29 January 2021
was granted 65,000 shares of Atreca (a derivative holding)SEC Form 428 February 2020Employee stock option (right to buy) · traded 26 February 2020 · filed 28 February 2020
was granted 45,000 shares of Atreca (a derivative holding)SEC Form 417 July 2019Stock Option (right to buy) · traded 11 July 2019 · filed 17 July 2019

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.